Omnipaque
Drug
GE HEALTHCARE
Total Payments
$15,459
Transactions
3
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $13,983 | 1 | 0 |
| 2023 | $1,176 | 1 | 0 |
| 2021 | $300.00 | 1 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $15,459 | 3 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Contrast-Enhanced Mammography Imaging Screening | GE HEALTHCARE | $13,983 | 0 |
| CMIST: Contrast Enhanced Mammography Imaging Screening Trial (CMIST) | GE HEALTHCARE | $1,176 | 0 |
| Low-osmolar contrast tagging in minimal cathartic CT colonography | GE HEALTHCARE | $300.00 | 0 |
Top Doctors Receiving Payments for Omnipaque
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Bronx, NY | $15,459 | 3 |
Ad
Manufacturing Companies
- GE HEALTHCARE $15,459
Product Information
- Type Drug
- Total Payments $15,459
- Total Doctors 0
- Transactions 3
About Omnipaque
Omnipaque is a drug associated with $15,459 in payments to 0 healthcare providers, recorded across 3 transactions in the CMS Open Payments database. The primary manufacturer is GE HEALTHCARE.
Payment data is available from 2021 to 2024. In 2024, $13,983 was paid across 1 transactions to 0 doctors.
The most common payment nature for Omnipaque is "Unspecified" ($15,459, 100.0% of total).
Omnipaque is associated with 3 research studies, including "Contrast-Enhanced Mammography Imaging Screening" ($13,983).